Panobinostat
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 202151

CAS#: 404950-80-7

Description: Panobinostat, also known as NVP LBH-589 or LBH-589, is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. On 2/23/2015, it received FDA accelerated approval for use in patients with multiple myeloma who had received at least 2 previous treatments, including bortezomib and an immunomodulatory agent.


Price and Availability

Size
Price

100mg
USD 110
1g
USD 550
10g
USD 2950
Size
Price

200mg
USD 190
2g
USD 950
20g
USD 3850
Size
Price

500mg
USD 350
5g
USD 1950
50g
Ask price

Panobinostat (LBH-589), purity > 98%, is in stock. The same day shipping out after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international). Note: the estimated shipping out time for order > 2 g may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 202151
Name: Panobinostat
CAS#: 404950-80-7
Chemical Formula: C21H23N3O2
Exact Mass: 349.17903
Molecular Weight: 349.43
Elemental Analysis: C, 72.18; H, 6.63; N, 12.03; O, 9.16


Synonym: LBH589; LBH 589; LBH-589; NVP-LBH589; NVP-LBH 589; Panobinostat; trade name Farydak

IUPAC/Chemical Name: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide

InChi Key: FPOHNWQLNRZRFC-ZHACJKMWSA-N

InChi Code: InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+

SMILES Code: O=C(NO)/C=C/C1=CC=C(CNCCC2=C(C)NC3=C2C=CC=C3)C=C1


Technical Data

Appearance:
White to off-white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Panobinostat has been found to synergistically act with sirolimus to kill pancreatic cancer cells in the laboratory in a Mayo Clinic study. In the study, investigators found that this combination destroyed up to 65 percent of cultured pancreatic tumor cells. The finding is significant because the three cell lines studies were all resistant to the effects of chemotherapy – as are many pancreatic tumors. see http://en.wikipedia.org/wiki/Panobinostat.  
 
 


References

 1: Andreu-Vieyra CV, Berenson JR. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol. 2014 Dec;5(6):197-210. doi: 10.1177/2040620714552614. Review. PubMed PMID: 25469210; PubMed Central PMCID: PMC4250267.

2: Li X, Zhang J, Xie Y, Jiang Y, Yingjie Z, Xu W. Progress of HDAC inhibitor panobinostat in the treatment of cancer. Curr Drug Targets. 2014 Jun;15(6):622-34. Review. PubMed PMID: 24597570.

3: Anne M, Sammartino D, Barginear MF, Budman D. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther. 2013 Nov 15;6:1613-24. doi: 10.2147/OTT.S30773. eCollection 2013. Review. PubMed PMID: 24265556; PubMed Central PMCID: PMC3833618.

4: Khot A, Dickinson M, Prince HM. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs. 2013 Sep;22(9):1211-23. doi: 10.1517/13543784.2013.815165. Epub 2013 Jul 3. Review. PubMed PMID: 23826641.

5: Neri P, Bahlis NJ, Lonial S. Panobinostat for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2012 May;21(5):733-47. doi: 10.1517/13543784.2012.668883. Epub 2012 Mar 12. Review. PubMed PMID: 22404247.

6: Oki Y, Copeland A, Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol. 2011 Jun;4(3):245-52. doi: 10.1586/ehm.11.24. Review. PubMed PMID: 21668391.

7: Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009 Jun;5(5):601-12. doi: 10.2217/fon.09.36. Review. PubMed PMID: 19519200.

8: Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009 Aug 8;280(2):233-41. doi: 10.1016/j.canlet.2009.02.019. Epub 2009 Apr 2. Review. PubMed PMID: 19344997.